ABBV vs ZBIO · P/E 81, rev $16.99B vs rev $10.0M
AbbVie Inc (ABBV) versus Zenas BioPharma, Inc. Common Stock (ZBIO) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
Latest reported ABBV revenue for 2026-06-30 was $16.99B. Net income was $3.61B. Revenue was up 13.3% from 2026-03-31 to 2026-06-30. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported ZBIO revenue for 2025-12-31 was $10.0M. Net income was -$377.7M. Revenue was up 100.0% from 2024-12-31 to 2025-12-31. ZBIO currently screens at market cap $798.0M.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. ZBIO currently screens at market cap $798.0M.
Not investment advice. Open the ABBV and ZBIO stock pages for the full models.
Not investment advice.